Buccal Drug Delivery Systems Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

Buccal Drug Delivery Systems Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

Global Buccal Drug Delivery Systems Market size will expand at an 8.6% CAGR from 2024 to 2032, fueled by the increasing prevalence of diabetes and cardiovascular diseases.

Buccal drug delivery systems are being crafted as a non-invasive alternative for medication administration, ensuring improved absorption and quicker action onset. By utilizing the mouth's mucous membranes for drug delivery, these systems boost patient compliance and convenience, especially for those needing frequent doses or struggling with oral tablets. As per WHO, cardiovascular diseases (CVDs) lead to global mortality, accounting for around 17.9 million deaths annually. In this context, buccal drug delivery systems are positioning themselves as a potent solution, promising swift medication absorption and heightened patient compliance for CVD management.

The market is segregated into product type, application, system type, end-use, and region.

In terms of product type, the buccal gels segment in the buccal drug delivery systems industry will grow at a considerable CAGR through 2032. This surge is driven by the rising demand for innovative medication administration methods. Formulated for controlled and sustained drug release via the buccal mucosa, buccal gels aim to boost absorption and therapeutic effectiveness. Ongoing advancements in gel formulations are fine-tuning release profiles and ingredient stability, further amplifying the efficacy of the systems.

By application, the buccal drug delivery systems market share from the neurological disorders segment is projected to rise from 2024 to 2032. This growth is attributed to the rising demand for specialized formulations and technologies. By delivering drugs via the buccal mucosa, these systems ensure rapid absorption and sidestep first-pass metabolism, a critical factor for central nervous system medications. Such an approach not only bolsters the management of neurological conditions but also guarantees improved bioavailability and patient adherence.

Regionally, the Europe buccal drug delivery systems industry size is projected to witness a significant CAGR between 2024 and 2032 due to the growing patient preference for alternative routes of administration. Buccal drug delivery enhances medication adherence by providing faster absorption and minimizing gastrointestinal side effects. Furthermore, regional advancements are focused on crafting more potent formulations and technologies to elevate drug stability and release profiles.